Down regulation of CD24 and HER-2/neu in breast carcinoma cells by activated human dendritic cell. Role of STAT3

Cellular Immunology

Volumn 275, Issue 1-2, 2012, Pages 69-79

  Hira, Sumit Kumar ^a   Manna, Partha Pratim ^a  

^a BANARAS HINDU UNIVERSITY   (India)

Author keywords

Apoptosis; CD24; Dendritic cell; HER 2 neu and STAT3

Indexed keywords

BETA ACTIN; CD24 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA INTERFERON; INTERLEUKIN 15; LIPOPOLYSACCHARIDE; SMALL INTERFERING RNA; STAT3 PROTEIN;

APOPTOSIS; ARTICLE; BREAST CARCINOMA; CARCINOMA CELL; CELL ACTIVATION; CONTROLLED STUDY; DENDRITIC CELL; DOWN REGULATION; HUMAN; HUMAN CELL; METASTASIS INHIBITION; ONCOGENE NEU; PRIORITY JOURNAL;

ANTIGENS, CD24; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; DENDRITIC CELLS; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; RECEPTOR, ERBB-2; STAT3 TRANSCRIPTION FACTOR;

EID: 84860545903     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2012.02.015     Document Type: Article

References (45)

1. Gilboa E. DC-based cancer vaccines. J. Clin. Invest. 2007, 117:1195-1203.
2. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 392:245-252.
3. Banchereau J., Briere F., Caux C., Davoust J., Lebecque S., Liu Y.J., Pulendran B., Palucka K. Immunobiology of dendritic cells. Annu. Rev. Immunol. 2000, 18:767-811.
4. Timmerman J.M., Levy R. Dendritic cell vaccines for cancer immunotherapy. Annu. Rev. Med. 1999, 50:507-529.
5. Geiger J., Hutchinson R., Hohenkirk L., McKenna E., Chang A., Mule J. Treatment of solid tumours in children with tumour-lysate-pulsed dendritic cells. Lancet 2000, 356:1163-1165.
6. Geiger J.D., Hutchinson R.J., Hohenkirk L.F., McKenna E.A., Yanik G.A., Levine J.E., Chang A.E., Braun T.M., Mule J.J. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res. 2001, 61:8513-8519.
7. Jarnjak-Jankovic S., Pettersen R.D., Saeboe-Larssen S., Wesenberg F., Olafsen M.R., Gaudernack G. Preclinical evaluation of autologous dendritic cells transfected with mRNA or loaded with apoptotic cells for immunotherapy of high-risk neuroblastoma. Cancer Gene Ther. 2005, 12:699-707.
8. Boczkowski D., Nair S.K., Nam J.H., Lyerly H.K., Gilboa E. Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res. 2000, 60:1028-1034.
9. Heiser A., Maurice M.A., Yancey D.R., Wu N.Z., Dahm P., Pruitt S.K., Boczkowski D., Nair S.K., Ballo M.S., Gilboa E., Vieweg J. Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA. J. Immunol. 2001, 166:2953-2960.
10. Heiser A., Coleman D., Dannull J., Yancey D., Maurice M.A., Lallas C.D., Dahm P., Niedzwiecki D., Gilboa E., Vieweg J. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J. Clin. Invest. 2002, 109:409-417.
11. Aspord C., Pedroza-Gonzalez A., Gallegos M., Tindle S., Burton E.C., Su D., Marches F., Banchereau J., Palucka A.K. Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4+T cells that facilitate tumor development. J. Exp. Med. 2007, 204:1037-1047.
12. Bell D., Chomarat P., Broyles D., Netto G., Harb G.M., Lebecque S., Valladeau J., Davoust J., Palucka K.A., Banchereau J. In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J. Exp. Med. 1999, 190:1417-1426.
13. Verhasselt V., Buelens C., Willems F., De G.D., Haeffner-Cavaillon N., Goldman M. Bacterial lipopolysaccharide stimulates the production of cytokines and the expression of costimulatory molecules by human peripheral blood dendritic cells: evidence for a soluble CD14-dependent pathway. J. Immunol. 1997, 158:2919-2925.
14. Becker Y. Anticancer role of dendritic cells (DC) in human and experimental cancers-a review. Anticancer Res. 1992, 12:511-520.
15. Gabrilovich D.I., Chen H.L., Girgis K.R., Cunningham H.T., Meny G.M., Nadaf S., Kavanaugh D., Carbone D.P. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 1996, 2:1096-1103.
16. Chapoval A.I., Tamada K., Chen L. In vitro growth inhibition of a broad spectrum of tumor cell lines by activated human dendritic cells. Blood 2000, 95:2346-2351.
17. Fanger N.A., Maliszewski C.R., Schooley K., Griffith T.S. Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J. Exp. Med. 1999, 190:1155-1164.
18. Josien R., Heslan M., Soulillou J.P., Cuturi M.C. Rat spleen dendritic cells express natural killer cell receptor protein 1 (NKR-P1) and have cytotoxic activity to select targets via a Ca2+dependent mechanism. J. Exp. Med. 1997, 186:467-472.
19. Suss .G., Shortman K. A subclass of dendritic cells kills CD4 T cells via Fas/Fas-ligand-induced apoptosis. J. Exp. Med. 1996, 183:1789-1796.
20. Manna P.P., Mohanakumar T. Human dendritic cell mediated cytotoxicity against breast carcinoma cells in vitro. J. Leukocyte Biol. 2002, 72:312-320.
21. Fogel M., Friederichs J., Zeller Y., Husar M., Smirnov A., Roitman L., Altevogt P., Sthoeger Z.M. CD24 is a marker for human breast carcinoma. Cancer Lett. 1999, 143:87-94.
22. Droz D., Rousseau-Merck M.F., Jaubert F., Diebold N., Nezelof C., Adafer E., Mouly H. Cell differentiation in Wilms' tumor (nephroblastoma): an immunohistochemical study. Hum. Pathol. 1990, 21:536-544.
23. Perri R.T., Royston I., LeBien T.W., Kay N.E. Chronic lymphocytic leukemia progenitor cells carry the antigens T65, BA-1 and Ia. Blood 1983, 61:871-875.
24. Huang L.R., Hsu H.C. Cloning and expression of CD24 gene in human hepatocellular carcinoma: a potential early tumor marker gene correlates with p53 mutation and tumor differentiation. Cancer Res. 1995, 55:4717-4721.
25. Lavabre-Bertrand T., Duperray C., Brunet C., Poncelet P., Exbrayat C., Bourquard P., Lavabre-Bertrand C., Brochier J., Navarro M., Janossy G. Quantification of CD24 and CD45 antigens in parallel allows a precise determination of B-cell maturation stages: relevance for the study of B-cell neoplasias. Leukemia 1994, 8:402-408.
26. Aigner S., Sthoeger Z.M., Fogel M., Weber E., Zarn J., Ruppert M., Zeller Y., Vestweber D., Stahel R., Sammar M., Altevogt P. CD24, a mucin-type glycoprotein, is a ligand for P-selectin on human tumor cells. Blood 1997, 89:3385-3395.
27. Menard S., Tagliabue E., Campiglio M., Pupa S.M. Role of HER2 gene overexpression in breast carcinoma. J. Cell Physiol. 2000, 182:150-162.
28. Morote J., de T., Caceres I.C., Vallejo C., Schwartz S., Reventos J. Prognostic value of immunohistochemical expression of the c-erbB-2 oncoprotein in metastasic prostate cancer. Int. J. Cancer 1999, 84:421-425.
29. Ross J.S., Yang F., Kallakury B.V., Sheehan C.E., Ambros R.A., Muraca P.J. HER-2/neu oncogene amplification by fluorescence in situ hybridization in epithelial tumors of the ovary. Am. J. Clin. Pathol. 1999, 111:311-316.
30. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182.
31. Kominsky S.L., Hobeika A.C., Lake F.A., Torres B.A., Johnson H.M. Down-regulation of neu/HER-2 by interferon-gamma in prostate cancer cells. Cancer Res. 2000, 60:3904-3908.
32. Bromberg J., Darnell J.E. The role of STATs in transcriptional control and their impact on cellular function. Oncogene 2000, 19:2468-2473.
33. Yu C.L., Meyer D.J., Campbell G.S., Larner A.C., Carter-Su C., Schwartz J., Jove R. Enhanced DNA-binding activity of a STAT3-related protein in cells transformed by the Src oncoprotein. Science 1995, 269:81-83.
34. Yu H., Jove R. The STATs of cancer-new molecular targets come of age. Nat. Rev. Cancer 2004, 4:97-105.
35. Kortylewski M., Kujawski M., Wang T., Wei S., Zhang S., Pilon-Thomas S., Niu G., Kay H., Mule J., Kerr W.G., Jove R., Pardoll D., Yu H. Inhibiting STAT3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat. Med. 2005, 11:1314-1321.
36. Nabarro S., Himoudi N., Papanastasiou A., Gilmour K., Gibson S., Sebire N., Thrasher A., Blundell M.P., Hubank M., Canderan G., Anderson J. Coordinated oncogenic transformation and inhibition of host immune responses by the PAX3-FKHR fusion oncoprotein. J. Exp. Med. 2005, 202:1399-1410.
37. Wang T., Niu G., Kortylewski M., Burdelya L., Shain K., Zhang S., Bhattacharya R., Gabrilovich D., Heller R., Coppola D., Dalton W., Jove R., Pardoll D., Yu H. Regulation of the innate and adaptive immune responses by STAT-3 signaling in tumor cells. Nat. Med. 2004, 10:48-54.
38. Sumimoto H., Imabayashi F., Iwata T., Kawakami Y. The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J. Exp. Med. 2006, 203:1651-1656.
39. Vicari A.P., Chiodoni C., Vaure C., it-Yahia S., Dercamp C., Matsos F., Reynard O., Taverne C., Merle P., Colombo M.P., O'Garra A., Trinchieri G., Caux C. Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. J. Exp. Med. 2002, 196:541-549.
40. Nefedova Y., Nagaraj S., Rosenbauer A., Muro-Cacho C., Sebti S.M., Gabrilovich D.I. Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway. Cancer Res. 2005, 65:9525-9535.
41. Catlett-Falcone R., Landowski T.H., Oshiro M.M., Turkson J., Levitzki A., Savino R., Ciliberto G., Moscinski L., Fernandez-Luna J.L., Nunez G., Dalton W.S., Jove R. Constitutive activation of STAT3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999, 10:105-115.
42. Xu Q., Briggs J., Park S., Niu G., Kortylewski M., Zhang S., Gritsko T., Turkson J., Kay H., Semenza G.L., Cheng J.Q., Jove R., Yu H. Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene 2005, 24:5552-5560.
43. Alshamsan A., Hamdy S., Haddadi A., Samuel J., El-Kadi A.O., Uludag H., Lavasanifar A. STAT3 knockdown in B16 melanoma by siRNA lipopolyplexes induces bystander immune response in vitro and in vivo. Trans. Oncol. 2011, 4:178-188.
44. Liao D., Liu Z., Wrasidlo W.J., Luo Y., Nguyen G., Chen T., Xiang R., Reisfeld R.A. Targeted therapeutic remodeling of the tumor microenvironment improves an HER-2 DNA vaccine and prevents recurrence in a murine breast cancer model. Cancer Res. 2011, 71:5688-5696.
45. Snyder M., Huang X.Y., Zhang J.J. Signal transducers and activators of transcription 3 (STAT3) directly regulates cytokine-induced fascin expression and is required for breast cancer cell migration. J. Biol. Chem. 2011, 286:38886-38893.